ESPE Yearbook of Paediatric Endocrinology

Brief summary: This randomized, double-blind, phase 3 trial of youths with inadequately controlled T2D, dulaglutide treatment was superior to placebo in reducing the glycated hemoglobin level at 26 weeks.Comment: T2D in children and adolescents is an aggressive disease with early onset of complications, leading to significant morbidity and mortality. After three decades with no efficient treatment, there is finally light at the end of the tunnel.<p c...

Brief summary: This study examined glycemic control following treatment with once-weekly exenatide 2 mg (Bydureon, AstraZeneca) in youth with T2D which was not optimally controlled. At 24 weeks, exenatide was superior to placebo in lowering HbA1c (least squares mean change, −0.36% with exenatide vs. +0.49% with placebo), with a between-group difference of −0.85%.Comment: The story of the development of exenatide is fascinating. It starts with...

Brief summary: In this study of 699 youth 10 to < 18 years old with <2 years duration of type 2 diabetes (T2D) at 15 centers across the USA, baseline HbA1c level, and the change in HbA1c level in the first 6 months are predictors of rapid glycemic deterioration. In addition, subsequent loss of control can be predicted based on both baseline and ongoing clinical characteristics.Comment: The population of individuals with youth-onset T2D is heterog...

Brief summary: This analysis of data from the TODAY study examined the impact of parental diabetes on outcomes in young individuals with T2D during over 12 years of follow-up. This novel observation demonstrates that parental diabetes affects not only earlier T2D onset, but also more rapid long-term progression and more complications.Comment: This study showed that T2D diagnosis in either parent was associated with younger age at T2D diagnosis in their c...

Brief summary: MiTy Kids is a prospective cohort study of children who were exposed to metformin during pregnancy. At 24 months, no difference was observed between those exposed to metformin and a placebo group, in BMI trajectories, mean BMI Z-score, or mean sum of skinfolds. Among those exposed to metformin, the BMI was higher among males than females.Comment: Metformin is increasingly used during pregnancy in women with T2D, but data on its lo...